Sökning: "Per Olsson Gisleskog"

Hittade 2 avhandlingar innehållade orden Per Olsson Gisleskog.

  1. 1. Clinical pharmacokinetic/pharmacodynamic modelling of 5a-reductase inhibitors for the treatment of benign prostatic hyperplasia

    Författare :Per Olsson Gisleskog; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacy; FARMACI; PHARMACY; FARMACI; Biopharmaceutics; biofarmaci;

    Sammanfattning : Dihydrotestosterone (DHT), a potent androgen necessary for the development of benign prostatic hyperplasia (BPH) is formed from testosterone by the enzyme 5α-reductase, of which there are two types. The irreversible 5α-reductase inhibitors dutasteride, which inhibits both isozymes, and finasteride, which inhibits only one, are intended for the treatment of BPH. LÄS MER

  3. 2. Pharmacometric Investigations of Prediction Precision and Advances of Models for Composite Scale Data

    Författare :Gustaf Wellhagen; Maria C. Kjellsson; Bengt Hamrén; Per Olsson Gisleskog; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacometrics; modelling; non-linear mixed effects modelling; composite scale data; total score data; total score analysis; precision prediction; bounded integer; bounded integer model; IRT-informed total score analysis; item response theory-informed; mixed models for repeated measures; MMRM; dose-response; dose-response mixed models for repeated measures; DR-MMRM; HbA1c models; fit-for-purpose analysis; clinical trial analysis; Farmaceutisk vetenskap; Pharmaceutical Science;

    Sammanfattning : Clinical trials are needed to evaluate new treatments. In late-stage clinical trials, failures are mostly due to lack of efficacy. Fit-for-purpose analysis methods will likely increase the success rates and advance drug development by providing higher precision to support decisions such as go/no-go, dose selection, or sample size. LÄS MER